Effective Use of Dupilumab in Managing Systemic Allergic Contact Dermatitis

Shyam Joshi, David A. Khan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Allergic contact dermatitis to metals has become increasingly recognized in patients with endovascular implants. The ACD can lead to in-stent restenosis as well as a prominent eczematous reaction overlying the implant, often necessitating its removal. We present a case of refractory allergic contact dermatitis to nickel in a 44-year-old man with numerous endovascular stents and vascular clips. He developed numerous adverse effects of systemic therapy to manage his symptoms including recurrent infections leading to frequent hospitalizations. He was effectively transitioned to dupilumab, a monoclonal antibody against the IL-4α subunit currently approved by the Food and Drug Administration in the management of atopic dermatitis, with an improvement in symptoms and a reduction in infection rate.

Original languageEnglish (US)
Pages (from-to)282-284
Number of pages3
JournalDermatitis
Volume29
Issue number5
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Allergic Contact Dermatitis
Stents
United States Food and Drug Administration
Atopic Dermatitis
Infection
Nickel
Surgical Instruments
Interleukin-4
Blood Vessels
Hospitalization
Metals
Monoclonal Antibodies
SAR231893
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Dermatology

Cite this

Effective Use of Dupilumab in Managing Systemic Allergic Contact Dermatitis. / Joshi, Shyam; Khan, David A.

In: Dermatitis, Vol. 29, No. 5, 01.09.2018, p. 282-284.

Research output: Contribution to journalArticle

@article{ad0f04a4f2084a309a6dd170043617b9,
title = "Effective Use of Dupilumab in Managing Systemic Allergic Contact Dermatitis",
abstract = "Allergic contact dermatitis to metals has become increasingly recognized in patients with endovascular implants. The ACD can lead to in-stent restenosis as well as a prominent eczematous reaction overlying the implant, often necessitating its removal. We present a case of refractory allergic contact dermatitis to nickel in a 44-year-old man with numerous endovascular stents and vascular clips. He developed numerous adverse effects of systemic therapy to manage his symptoms including recurrent infections leading to frequent hospitalizations. He was effectively transitioned to dupilumab, a monoclonal antibody against the IL-4α subunit currently approved by the Food and Drug Administration in the management of atopic dermatitis, with an improvement in symptoms and a reduction in infection rate.",
author = "Shyam Joshi and Khan, {David A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1097/DER.0000000000000409",
language = "English (US)",
volume = "29",
pages = "282--284",
journal = "Dermatitis : contact, atopic, occupational, drug",
issn = "1710-3568",
publisher = "Decker Publishing",
number = "5",

}

TY - JOUR

T1 - Effective Use of Dupilumab in Managing Systemic Allergic Contact Dermatitis

AU - Joshi, Shyam

AU - Khan, David A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Allergic contact dermatitis to metals has become increasingly recognized in patients with endovascular implants. The ACD can lead to in-stent restenosis as well as a prominent eczematous reaction overlying the implant, often necessitating its removal. We present a case of refractory allergic contact dermatitis to nickel in a 44-year-old man with numerous endovascular stents and vascular clips. He developed numerous adverse effects of systemic therapy to manage his symptoms including recurrent infections leading to frequent hospitalizations. He was effectively transitioned to dupilumab, a monoclonal antibody against the IL-4α subunit currently approved by the Food and Drug Administration in the management of atopic dermatitis, with an improvement in symptoms and a reduction in infection rate.

AB - Allergic contact dermatitis to metals has become increasingly recognized in patients with endovascular implants. The ACD can lead to in-stent restenosis as well as a prominent eczematous reaction overlying the implant, often necessitating its removal. We present a case of refractory allergic contact dermatitis to nickel in a 44-year-old man with numerous endovascular stents and vascular clips. He developed numerous adverse effects of systemic therapy to manage his symptoms including recurrent infections leading to frequent hospitalizations. He was effectively transitioned to dupilumab, a monoclonal antibody against the IL-4α subunit currently approved by the Food and Drug Administration in the management of atopic dermatitis, with an improvement in symptoms and a reduction in infection rate.

UR - http://www.scopus.com/inward/record.url?scp=85053670060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053670060&partnerID=8YFLogxK

U2 - 10.1097/DER.0000000000000409

DO - 10.1097/DER.0000000000000409

M3 - Article

C2 - 30179979

AN - SCOPUS:85053670060

VL - 29

SP - 282

EP - 284

JO - Dermatitis : contact, atopic, occupational, drug

JF - Dermatitis : contact, atopic, occupational, drug

SN - 1710-3568

IS - 5

ER -